“The V-CHAMPS Challenge showed us that artificial intelligence (AI) models that performed well on the synthetic patient data in Phase 1 also performed well on the RWD during Phase 2, highlighting the potential value of using synthetic data in AI model development.”
The National Institute of Standards and Technology (NIST) is seeking input from industry to support its response to President Biden’s Executive Order on AI. Comments, which are due February 2, 2024, will help NIST develop guidelines for evaluation and red-teaming, consensus-based standards and more.
Even AI models trained on general medical literature will have difficulty making sense of the nuances specific to primary care, which is full of unique jargon, abbreviations and other idiosyncrasies. As always, the proverbial devil is in the details. Any AI solution worth its salt must be fluent in the specific idioms of the field and empower clinicians to deliver the best care that they can.
A recent survey by the AMA showed that practicing physicians are equally excited and concerned about the increased use of AI in health care, with enthusiasm for technologies that reduce administrative burden and enhance diagnostic ability and concern for patient privacy, liability and erosion of the patient-physician relationship.
The convergence of gamification and AI heralds a transformative era in mental health care, offering a blend of engagement and precision previously unattainable.
AI-driven regulatory platforms support SaMD organizations by proactively monitoring and adapting to the dynamic global regulatory landscape. The technology alerts users to anticipated regulatory updates worldwide, facilitating improved foresight and trend detection. It also provides guidance on addressing potential lapses in product compliance, integrates with existing workflows and streamlines regulatory tasks from classification to registration and market entry.
On October 30, President Biden issued an Executive Order establishing new standards for artificial intelligence (AI). The order focuses on safety and security, privacy protections, advancement of equity and civil rights, promotion of innovation and competition and advancing American leadership in AI.
While billion-dollar deals are common in the medtech industry, multi-billion-dollar megadeal acquisitions were still notable in 2022. Often, these deals result in a ripple effect on the industry when two large companies merge. Here we look at some recent examples, the growth drivers behind them and what they mean for the medtech industry.
The goal of the collaboration is to optimize the benefits of PCCPs by supporting predictability and harmonizing regulatory considerations across jurisdictions, and ultimately, put safe and effective advancements in the hands of healthcare providers and users faster.
Change control plans for AI/ML, remanufacturing of devices and medical device shortages are among the guidances the FDA Center for Devices and Radiological Health (CDRH) is prioritizing in 2024. The agency is seeking stakeholder feedback on the list of guidance documents it intends to publish in the coming year.
